The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research.
Malvern, US
Size (employees)
938 (est)
BioTelemetry was founded in 2013 and is headquartered in Malvern, US

BioTelemetry Office Locations

BioTelemetry has an office in Malvern
Malvern, US (HQ)
102 1000 Cedar Hollow Rd

BioTelemetry Data and Metrics

BioTelemetry Financial Metrics

BioTelemetry's revenue was reported to be $208.3 m in FY, 2016 which is a 17% increase from the previous period.

Revenue (FY, 2016)

208.3 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

129.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

53.4 m

EBIT (FY, 2016)

18 m

Market capitalization (20-Jul-2017)

1 b

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

23.1 m


1 b
BioTelemetry's current market capitalization is $1 b.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


119 m111.5 m129.5 m166.6 m178.5 m208.3 m

Revenue growth, %


Cost of goods sold

6.2 m5.1 m4.9 m73.1 m72 m78.9 m

Gross profit

112.8 m106.4 m124.6 m93.5 m106.6 m129.5 m

Gross profit Margin, %


Sales and marketing expense

28.6 m

R&D expense

8.4 m

General and administrative expense

55.9 m

Operating expense total

86 m97.8 m97 m111.4 m


(6.9 m)(4.3 m)9.5 m18 m

EBIT margin, %


Pre tax profit

(7.1 m)(12.1 m)15.8 m

Income tax expense

244 k(905 k)215 k37.7 m

Net Income

(7.3 m)(9.8 m)7.4 m53.4 m
USDY, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016


18.7 m18.3 m18.3 m22.2 m20 m19 m23.1 m


2.4 m2.4 m1.5 m5.2 m

Current Assets

44.3 m49.5 m47 m59.6 m


18.8 m21.7 m25.6 m25.8 m


16.5 m29.6 m29.8 m41.1 m

Total Assets

87.5 m124.8 m124.1 m199 m

Accounts Payable

8.7 m13.2 m8.5 m12.4 m

Total Debt

23.2 m25.3 m

Current Liabilities

19 m35.3 m23.9 m31.5 m

Total Liabilities

60.1 m

Additional Paid-in Capital

260.6 m267.2 m272.1 m281.6 m

Retained Earnings

(193.8 m)(203.6 m)(196.2 m)(142.7 m)

Total Equity

66.8 m63.7 m75.9 m138.9 m

Debt to Equity Ratio

0.3 x0.2 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

1.3 x2 x1.6 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(7.3 m)(9.8 m)7.4 m53.4 m

Depreciation and Amortization

12.3 m12.6 m12.5 m14.3 m

Accounts Receivable

(4.6 m)(13 m)(7.7 m)


340 k299 k188 k(753 k)

Accounts Payable

2.4 m47 k(4.7 m)3.1 m

Cash From Operating Activities

11.3 m8.8 m14.4 m38.9 m

Purchases of PP&E

(8.2 m)

Cash From Investing Activities

(8.2 m)(26.9 m)(13.6 m)(36.2 m)

Long-term Borrowings

(26.4 m)(1.4 m)

Cash From Financing Activities

763 k15.9 m(1.8 m)1.4 m

Interest Paid

132 k856 k1 m1.3 m

Income Taxes Paid

112 k148 k384 k359 k
USDY, 2016


55.6 x


25.8 x


222.1 k


0.2 x


0.1 x

Financial Leverage

1.4 x

BioTelemetry Operating Metrics

FY, 2015FY, 2016

Patents (foreign)


Patents Issued




Patents (US)


BioTelemetry Market Value History

BioTelemetry News and Updates

BioTelemetry Company Life and Culture

You may also be interested in